TY - JOUR T1 - Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis. JF - J Rheumatol Y1 - 2017 A1 - Simonini, Gabriele A1 - Bracaglia, Claudia A1 - Cattalini, Marco A1 - Taddio, Andrea A1 - Brambilla, Alice A1 - de Libero, Cinzia A1 - Pires Marafon, Denise A1 - Caputo, Roberto A1 - Cimaz, Rolando KW - Adolescent KW - Antirheumatic Agents KW - Autoimmune Diseases KW - Child KW - Child, Preschool KW - Female KW - Humans KW - Male KW - Predictive Value of Tests KW - Recurrence KW - Retrospective Studies KW - Treatment Outcome KW - Uveitis KW - Withholding Treatment AB -

OBJECTIVE: To identify clinical predictors of relapse in childhood autoimmune chronic uveitis after stopping systemic treatment.

METHODS: A retrospective, multicenter, cohort study.

RESULTS: Ninety-four children in remission, receiving no treatments and with at least a 6-month followup, were enrolled. A higher probability of maintaining remission after discontinuing treatment was shown in idiopathic compared with juvenile idiopathic arthritis uveitis (Mantel-Cox chi-square = 23.21) if inactivity had been obtained within 6 months from starting systemic treatment (Mantel-Cox chi-square = 24.17) and by antitumor necrosis factor-α treatment (Mantel-Cox chi-square = 6.43).

CONCLUSION: Type of disease, time, and type of systemic therapy to achieve inactivity predict different duration of uveitis remission after treatment withdrawal.

VL - 44 IS - 6 U1 - http://www.ncbi.nlm.nih.gov/pubmed/28365583?dopt=Abstract ER - TY - JOUR T1 - Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series. JF - Pediatr Rheumatol Online J Y1 - 2011 A1 - Taddio, Andrea A1 - Cimaz, Rolando A1 - Caputo, Roberto A1 - de Libero, Cinzia A1 - Di Grande, Laura A1 - Simonini, Gabriele A1 - Mori, Francesca A1 - Novembre, Elio A1 - Pucci, Neri AB -

Uveitis treatment involves topical corticosteroids along with cycloplegic-mydriatics. Particularly severe cases may require systemic corticosteroids and immunosuppressive drugs. Vernal keratoconjunctivitis (VKC) treatment consists of a brief period of topical corticosteroids and/or cyclosporine. In patients refractory to traditional treatment, the use of 0.1% topical ophtalmic FK- 506 (tacrolimus) ointment has been occasionally reported.This is the first report of the coexistence of uveitis and VKC. The documented response to topical tacrolimus eyedrop of uveitis and VKC is also of interest, in particular since to our knowledge there are no published reports on its clinical use in uveitis.

VL - 9 IS - 1 U1 - http://www.ncbi.nlm.nih.gov/pubmed/22047067?dopt=Abstract ER -